| Authors: |
Penny HL; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States., Hainline K; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States., Theoharis N; Labcorp, Translational Biomarker Solutions, Greenfield, IN, United States., Wu B; Department of Biologics, Amgen, Thousand Oaks, CA, United States., Brandl C; Department of Translational Safety & Bioanalytical Sciences, Amgen Research (Munich) GmbH, Munich, Germany., Webhofer C; Department of Process Development, Amgen Research (Munich) GmbH, Munich, Germany., McComb M; Department of Clinical Pharmacology, Modeling & Simulation, Amgen, Thousand Oaks, CA, United States., Wittemer-Rump S; Bayer AG, Research and Development Oncology (RED Onc), Pharmaceuticals, Berlin, Germany., Koca G; Bayer AG, Research and Development Oncology (RED Onc), Pharmaceuticals, Berlin, Germany., Stienen S; Department of Early Development (Oncology), Amgen Research (Munich) GmbH, Munich, Germany., Bargou RC; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Wurzburg, Wurzburg, Germany., Hummel HD; Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, University Hospital Wurzburg, Wurzburg, Germany., Loidl W; Department of Urology, Ordensklinikum Linz GmbH, Linz, Austria., Grüllich C; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Medical Center, Heidelberg, Germany., Eggert T; Department of Early Development (Oncology), Amgen, Thousand Oaks, CA, United States., Tran B; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Mytych DT; Department of Clinical Immunology, Amgen, Thousand Oaks, CA, United States. |
